$BFRI News

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Biofrontera Refiles Supplemental New Drug Application For Ameluz Topical Gel To FDA To Treat Actinic Keratoses

Transcript: Biofrontera Q2 2026 Earnings Conference Call

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Biofrontera Receives FDA Supplemental New Drug Application Approval For Its Ameluz Topical Gel, 10%, In Combination With Photodynamic Therapy Using The BF-RhodoLED Lamp Series For The Treatment Of Superficial Basal Cell Carcinoma In Adults

FDA Approves Label Update For Biofrontera’s Ameluz Gel To Highlight Hypersensitivity Warnings

Biofrontera (NASDAQ:BFRI) Passes Minervini Trend Template With High-Growth Momentum

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. Q2 2026 Earnings Call Summary

Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Biofrontera (BFRI) Q1 2026 Earnings Transcript

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3

Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI) Reports Q1 2026 Revenue and EPS Miss, Stock Falls in Pre-Market

Transcript: Biofrontera Q1 2026 Earnings Conference Call